191 related articles for article (PubMed ID: 29353549)
41. Molecular analysis of chromosome arm 17q gain in neuroblastoma.
Janoueix-Lerosey I; Penther D; Thioux M; de Crémoux P; Derré J; Ambros P; Vielh P; Bénard J; Aurias A; Delattre O
Genes Chromosomes Cancer; 2000 Jul; 28(3):276-84. PubMed ID: 10862033
[TBL] [Abstract][Full Text] [Related]
42. Gain of chromosome arm 17q predicts unfavourable outcome in neuroblastoma patients. U.K. Children's Cancer Study Group and the U.K. Cancer Cytogenetics Group.
Lastowska M; Cotterill S; Pearson AD; Roberts P; McGuckin A; Lewis I; Bown N
Eur J Cancer; 1997 Sep; 33(10):1627-33. PubMed ID: 9389925
[TBL] [Abstract][Full Text] [Related]
43. High-resolution analysis of allelic imbalance in neuroblastoma cell lines by single nucleotide polymorphism arrays.
Carr J; Bown NP; Case MC; Hall AG; Lunec J; Tweddle DA
Cancer Genet Cytogenet; 2007 Jan; 172(2):127-38. PubMed ID: 17213021
[TBL] [Abstract][Full Text] [Related]
44. Evidence for two tumour suppressor loci on chromosomal bands 1p35-36 involved in neuroblastoma: one probably imprinted, another associated with N-myc amplification.
Caron H; Peter M; van Sluis P; Speleman F; de Kraker J; Laureys G; Michon J; Brugières L; Voûte PA; Westerveld A
Hum Mol Genet; 1995 Apr; 4(4):535-9. PubMed ID: 7633401
[TBL] [Abstract][Full Text] [Related]
45. Correlation of modified Shimada classification with MYCN and 1p36 status detected by fluorescence in situ hybridization in neuroblastoma.
Altungoz O; Aygun N; Tumer S; Ozer E; Olgun N; Sakizli M
Cancer Genet Cytogenet; 2007 Jan; 172(2):113-9. PubMed ID: 17213019
[TBL] [Abstract][Full Text] [Related]
46. Detection of single-copy chromosome 17q gain in human neuroblastomas using real-time quantitative polymerase chain reaction.
Morowitz M; Shusterman S; Mosse Y; Hii G; Winter CL; Khazi D; Wang Q; King R; Maris JM
Mod Pathol; 2003 Dec; 16(12):1248-56. PubMed ID: 14681326
[TBL] [Abstract][Full Text] [Related]
47. Clinical evaluation of integrated panel testing by next-generation sequencing for somatic mutations in neuroblastomas with MYCN unamplification.
Cao Y; Jin Y; Yu J; Wang J; Qiu Y; Duan X; Ye Y; Cheng Y; Dong L; Feng X; Wang D; Li Z; Tian X; Wang H; Yan J; Zhao Q
Oncotarget; 2017 Jul; 8(30):49689-49701. PubMed ID: 28591696
[TBL] [Abstract][Full Text] [Related]
48. cDNA array-CGH profiling identifies genomic alterations specific to stage and MYCN-amplification in neuroblastoma.
Chen QR; Bilke S; Wei JS; Whiteford CC; Cenacchi N; Krasnoselsky AL; Greer BT; Son CG; Westermann F; Berthold F; Schwab M; Catchpoole D; Khan J
BMC Genomics; 2004 Sep; 5():70. PubMed ID: 15380028
[TBL] [Abstract][Full Text] [Related]
49. Prognostic value of partial genetic instability in neuroblastoma with ≤50% neuroblastic cell content.
Piqueras M; Navarro S; Cañete A; Castel V; Noguera R
Histopathology; 2011 Jul; 59(1):22-30. PubMed ID: 21668478
[TBL] [Abstract][Full Text] [Related]
50. An increased NM23H1 copy number may be a poor prognostic factor independent of LOH on 1p in neuroblastomas.
Takeda O; Handa M; Uehara T; Maseki N; Sakashita A; Sakurai M; Kanda N; Arai Y; Kaneko Y
Br J Cancer; 1996 Nov; 74(10):1620-6. PubMed ID: 8932344
[TBL] [Abstract][Full Text] [Related]
51. [Methods of detection and prognostic significance of genetic material increase of the short arm of chromosome 2 and a deletion of the short arm of chromosome 1 in patients with neuroblastoma].
Druĭ AE; Tsaur GA; Shorikov EV; Popov AM; Plekhanova OM; Typonogov SN; Savel'ev LI; Tsvirenko SV; Fechina LG
Vopr Onkol; 2013; 59(5):591-8. PubMed ID: 24260886
[TBL] [Abstract][Full Text] [Related]
52. Fluorescence in situ hybridization analyses of chromosome band 1p36 in neuroblastoma detect two classes of alterations.
Spitz R; Hero B; Westermann F; Ernestus K; Schwab M; Berthold F
Genes Chromosomes Cancer; 2002 Jul; 34(3):299-305. PubMed ID: 12007190
[TBL] [Abstract][Full Text] [Related]
53. Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci.
Pfister S; Remke M; Benner A; Mendrzyk F; Toedt G; Felsberg J; Wittmann A; Devens F; Gerber NU; Joos S; Kulozik A; Reifenberger G; Rutkowski S; Wiestler OD; Radlwimmer B; Scheurlen W; Lichter P; Korshunov A
J Clin Oncol; 2009 Apr; 27(10):1627-36. PubMed ID: 19255330
[TBL] [Abstract][Full Text] [Related]
54. Deletion of chromosome 1p loci and microsatellite instability in neuroblastomas analyzed with short-tandem repeat polymorphisms.
Martinsson T; Sjöberg RM; Hedborg F; Kogner P
Cancer Res; 1995 Dec; 55(23):5681-6. PubMed ID: 7585654
[TBL] [Abstract][Full Text] [Related]
55. Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project.
Schleiermacher G; Mosseri V; London WB; Maris JM; Brodeur GM; Attiyeh E; Haber M; Khan J; Nakagawara A; Speleman F; Noguera R; Tonini GP; Fischer M; Ambros I; Monclair T; Matthay KK; Ambros P; Cohn SL; Pearson AD
Br J Cancer; 2012 Oct; 107(8):1418-22. PubMed ID: 22976801
[TBL] [Abstract][Full Text] [Related]
56. Are gains of chromosomal regions 7q and 11p important abnormalities in neuroblastoma?
Stallings RL; Howard J; Dunlop A; Mullarkey M; McDermott M; Breatnach F; O'Meara A
Cancer Genet Cytogenet; 2003 Jan; 140(2):133-7. PubMed ID: 12645651
[TBL] [Abstract][Full Text] [Related]
57. Genome-wide examination of chromosomal aberrations in neuroblastoma SH-SY5Y cells by array-based comparative genomic hybridization.
Do JH; Kim IS; Park TK; Choi DK
Mol Cells; 2007 Aug; 24(1):105-12. PubMed ID: 17846504
[TBL] [Abstract][Full Text] [Related]
58. Biological characteristics of neuroblastoma with partial deletion in the short arm of chromosome 1.
Hiyama E; Hiyama K; Ohtsu K; Yamaoka H; Fukuba I; Matsuura Y; Yokoyama T
Med Pediatr Oncol; 2001 Jan; 36(1):67-74. PubMed ID: 11464909
[TBL] [Abstract][Full Text] [Related]
59. Co-expression analysis identifies long noncoding RNA SNHG1 as a novel predictor for event-free survival in neuroblastoma.
Sahu D; Hsu CL; Lin CC; Yang TW; Hsu WM; Ho SY; Juan HF; Huang HC
Oncotarget; 2016 Sep; 7(36):58022-58037. PubMed ID: 27517149
[TBL] [Abstract][Full Text] [Related]
60. The genetic tumor background is an important determinant for heterogeneous MYCN-amplified neuroblastoma.
Bogen D; Brunner C; Walder D; Ziegler A; Abbasi R; Ladenstein RL; Noguera R; Martinsson T; Amann G; Schilling FH; Ussowicz M; Benesch M; Ambros PF; Ambros IM
Int J Cancer; 2016 Jul; 139(1):153-63. PubMed ID: 26910568
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
